
51 - 200 employees
💼 Consulting
📣 Marketing
🧬 Biotechnology
Consulting • Marketing • Biotechnology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Our lead program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) aimed at treating estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company has recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250, supported by experienced scientists, board members, and leading healthcare investors.
🕒 July 2
Senior Medical Science Liaison for Olema Oncology engaging with key opinion leaders and healthcare providers. Facilitating scientific exchange and supporting medical affairs objectives within the Southeast Region.